Volume 9 Supplement 1

Proceedings of the 14th Annual Meeting of the Collaborative Group of the Americas on Inherited Colorectal Cancer

Open Access

Estimating probability of germline mismatch repair mutations in colorectal cancer patients with microsatellite stable tumors

  • Jessica N Everett1Email author,
  • Victoria M Raymond1,
  • Michele Gornick2,
  • Rajesh S Mangrulkar1,
  • Ignacio Blanco3 and
  • Stephen B Gruber4
Hereditary Cancer in Clinical Practice20119(Suppl 1):P12

DOI: 10.1186/1897-4287-9-S1-P12

Published: 10 March 2011

Background

Microsatellite instability (MSI) is a hallmark of DNA mismatch repair (MMR) deficiency and is an established screening tool for identifying Lynch syndrome in colorectal cancer populations [1]. However, MSI testing is neither perfectly sensitive nor specific to detect Lynch Syndrome, and germline MMR mutations have been reported in patients with microsatellite stable (MSS) tumors [2]. The value of germline MMR testing in patients with MSS tumors may vary based on family history, and data is needed to guide choices about when to offer testing in high risk clinic settings.

Materials and methods

From 2002-2009, high risk patients presenting to the Cancer Genetics Clinics at the University of Michigan and the Catalan Institute of Oncology in Barcelona, Spain were evaluated for Lynch syndrome and included in the present study. Patients with MSS colorectal tumors who also had germline MMR testing were eligible for analysis. We calculated risk for MMR mutation using MMRPro v.5.1[3] at baseline, after MSI testing, and after germline MMR testing. Modified likelihood ratios were estimated to evaluate the utility of germline testing in patients with MSS tumors based on the strength of the family history [4].

Results

Germline MMR mutations were identified in 5/44 (11.4%) patients with MSS tumors. Two of the mutations were identified in patients from families that met the Amsterdam Criteria (AC I/II), whereas 3 mutations were found in patients from families that were AC I/II negative. The modified likelihood for a germline mutation (+LRmod) in an AC I/II patient was 1.56 (95% CI: 0.47 - 5.18) and the modified negative likelihood ratio (-LRmod) for a patient not meeting the AC I/II criteria was 0.81 (95% CI: 0.39 - 1.69). We quantified the meaning of the AC I/II criteria to guide clinical choices about genetic testing in MSS tumors by multiplying the pretest odds by the +LRmod and the -LRmod. The probability of a mutation was modified from a baseline of 11.4% to 16.7% in AC I/II families, compared to 9.4% in AC I/II-negative families.

Conclusions

Germline MMR testing in high risk patients with MSS colorectal tumors identifies mutations in a small, but meaningful proportion of patients. The diagnostic yield is dependent on the strength of the family history. Modified likelihood ratios can be helpful to quantify the probability of a positive gene test for Lynch Syndrome, and can be applied to pre-test probabilities derived from clinical models.

Authors’ Affiliations

(1)
Department of Internal Medicine, University of Michigan
(2)
Department of Human Genetics, University of Michigan
(3)
Cancer Genetic Counseling Program, IDIBELL-Institut Català d’Oncologia
(4)
Department of Internal Medicine, Epidemiology, and Human Genetics, University of Michigan

References

  1. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la Chapelle A: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer). N Engl J Med 2005, 352: 1851–1860. 10.1056/NEJMoa043146PubMedView ArticleGoogle Scholar
  2. Lagerstedt Robinson K, Liu T, Vandrovcova J, Halvarsson B, Clendenning M, Frebourg T, Papadopoulos N, Kinzler KW, Vogelstein B, Peltomaki P, Kolodner RD, Nilbert M, Lindblom A: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) diagnostics. JNCI 2007, 99: 291–299.PubMedView ArticleGoogle Scholar
  3. Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, Watson P, Gruber SB, Euhus D, Kinzler KW, Jass J, Gallinger S, Lindor NM, Casey G, Ellis N, Giardiello FM, Offit K, Parmigiani G: Prediction of germline mutations and cancer risk in the Lynch Syndrome. JAMA 2006, 296: 1479–1487. 10.1001/jama.296.12.1479PubMed CentralPubMedView ArticleGoogle Scholar
  4. Simel DL, Samsa GP, Matchar DB: Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 1991, 44: 763–770. 10.1016/0895-4356(91)90128-VPubMedView ArticleGoogle Scholar

Copyright

© Everett et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement